CTOs on the Move

ImmunityBio

www.immunitybio.com

 
ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Enrique Dilone
Chief Technology Officer Profile

Similar Companies

Benjamin Biomedical Inc

Benjamin Biomedical Inc is a St Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NephroGenex

NephroGenex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Obatala Sciences

Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.